35 Key Corporate Highlights Advancing Novel Therapies for Diseases with High Unmet Needs Expected Upcoming Milestones Focus on diseases with well-defined mechanistic Phase 3 LUCIDITY topline data Q3 2026 Avexitide PBH Clinical anticipated in Q3 2026 rationale, clear clinical outcomes and biomarkers, and rigorous preclinical data Commercial launch, if approved, 2027 Avexitide PBH Regulatory anticipated in 2027 First-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug AVEXITIDE designations Phase 1 LUMINA trial Cohort 1 (n=12) biomarker data to be presented at a 1H 2026 AMX0114 ALS Clinical Oral, fixed-dose combination of two medical meeting expected in 1H 2026 small molecules, sodium AMX0035 phenylbutyrate and taurursodiol PBH & Rare IND-enabling studies underway with an Antisense oligonucleotide designed to 2027 AMX0318 Preclinical target calpain-2, a protein involved in IND filing targeted for 2027 Diseases AMX0114 axonal degeneration & neurofilament biology with FDA Fast Track Designation Novel, long-acting GLP-1 AMX0318 receptor antagonist ALS=amyotrophic lateral sclerosis
Allow vials to reach room temperature before opening to reduce condensation absorption
Orforglipron met ATTAIN-1s primary endpoint by lowering weight by an average of 12.4% (27.3 lbs) vs
Studies on the benefits of ipamorelin have demonstrated the following anti-aging benefits: Increase bone density (Svensson et al., 2000) Increases body fat loss in obese adults (Kim et al, 1999) Increased muscle mass (Andersen et al, 2001) Enhanced immune system Boosting of cellular protein synthesis (neolab Research, 2015) Why Combine Sermorelin and Ipamorelin
The antioxidant is present in a number of common foods, including eggs, nuts, legumes, fish and chicken
Mistakes I see repeatedly: On the topical side: applying to damp skin, layering acids immediately, using too little product (a barely-visible film isn't enough), and leaving reconstituted products at room temperature for weeks
